Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
February 28, 2023 4:06 PM ESTQ4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively. Q4 and full year 2022 RHA® Collection revenue of $34.8 million and $107.2 million, a YoY increase of 46% and 51%, respectively. DAXXIFY® Q4 PrevU revenue of $11.0 million, with commercial launch to begin late March 2023. PDUFA date for DAXXIFY® for the treatment of cervical dystonia of August 19, 2023. Appointed Dr. Vlad Coric, M.D., Chairman and CEO of Biohaven, to the companys Board of Directors. Conference call and webcast today at 4:30 p.m. ET.
NASHVILLE, Tenn.--(BUSINESS... More
